Suppr超能文献

合成硫代磷酸寡核苷酸对映异构体的二维顺序选择手性×反相液相色谱法。

Two-dimensional sequential selective comprehensive chiral×reversed-phase liquid chromatography of synthetic phosphorothioate oligonucleotide diastereomers.

机构信息

Institute of Pharmaceutical Sciences, Pharmaceutical (Bio-)Analysis, University of Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany.

Bayer AG, Pharmaceutical Division, Friedrich-Ebert-Strasse 217-333 42117 Wuppertal, Germany.

出版信息

J Chromatogr A. 2024 Aug 16;1730:465076. doi: 10.1016/j.chroma.2024.465076. Epub 2024 Jun 11.

Abstract

In recent years, many nucleic acid-based pharmaceuticals have been approved and entered the market, and even a larger number are in late stage clinical trials. Conventional oligonucleotides are facing issues in vivo like fast renal clearance and nuclease degradation. Therefore, to increase their stability, phosphorothioation is a frequent modification of therapeutic oligonucleotides (ONs) which also leads to improved binding affinity facilitating cell internalization and intracellular distribution. At the same time, by replacing a phosphodiester linkage with a phosphorothioate group, a phosphorous stereogenic center is generated which causes the formation of R- and S-diastereomers. It increases the structural diversity. For example, with 15 of those phosphorothioate (PS) linkages, 32,768 different diastereomers are expected. Since the phosphorothioate is introduced non-stereoselectively, the molecular complexity of the resultant phosphorothioate ON products is tremendously increased impeding the chromatographic separation in the course of quality control. Since distinct phosphorothioate diastereomers have different bioactivities and pharmacological properties, there is increasing interest in implications of stereoisomerism of phosphorothiate oligonucleotides. From a quality and regulatory viewpoint, batch-to-batch reproducibility of the diastereomer profile may be of significant concern. In order to address this issue, this study investigates the stereoselectivity of LC methods for two phosphorothioate oligonucleotide (PSO) compounds differing in their molecular size and numbers of PS linkages. Diastereoselectivity of ion-pairing reversed-phase liquid chromatography (IP-RPLC), RPLC without ion-pairing agents and LC with chiral polysaccharide-based column were evaluated for model PSOs and an active pharmaceutical ingredient (API) of PSO with trivalent N-acetylgalactosamine (GalNAc) conjugate. Due to the structural complexity of PSOs, the separation power for the diastereomer mixture was increased by using sequential selective comprehensive two-dimensional chromatography with an amylose tris(α-methylbenzylcarbamate)-immobilized chiral stationary phase (CSP) in the first dimension and ion-pair RPLC with ethylammonium acetate in the second dimension. Improved diastereomer selectivity was obtained and a larger number of peaks could be separated.

摘要

近年来,许多基于核酸的药物已获得批准并进入市场,还有更多的药物处于后期临床试验阶段。传统的寡核苷酸在体内会面临诸如快速肾清除和核酸酶降解等问题。因此,为了提高其稳定性,硫代磷酸化是治疗性寡核苷酸(ONs)的常见修饰方法,这也导致结合亲和力提高,促进细胞内化和细胞内分布。同时,通过用硫代磷酸酯基团替代磷酸二酯键,会产生一个磷立体中心,从而导致 R-和 S-非对映异构体的形成。这增加了结构的多样性。例如,用 15 个硫代磷酸酯(PS)键,预计会形成 32768 种不同的非对映异构体。由于硫代磷酸酯是非立体选择性引入的,因此所得硫代磷酸酯 ON 产物的分子复杂性大大增加,在质量控制过程中阻碍了色谱分离。由于不同的硫代磷酸酯非对映异构体具有不同的生物活性和药理学性质,因此人们越来越关注硫代磷酸酯寡核苷酸的立体异构体问题。从质量和监管的角度来看,非对映异构体谱的批间重现性可能是一个重要问题。为了解决这个问题,本研究考察了两种硫代磷酸酯寡核苷酸(PSO)化合物的 LC 方法的立体选择性,这两种化合物在分子大小和 PS 键数量上有所不同。考察了离子对反相液相色谱(IP-RPLC)、无离子对试剂的 RPLC 和手性多糖基柱的 LC 对模型 PSO 和具有三价 N-乙酰半乳糖胺(GalNAc)缀合物的 PSO 原料药(API)的非对映选择性。由于 PSO 结构复杂,通过在第一维中使用具有淀粉三(α-甲基苄基氨基甲酸酯)固定相的顺序选择性综合二维色谱,以及在第二维中使用乙铵乙酸盐离子对 RPLC,增加了非对映异构体混合物的分离能力。获得了更好的非对映选择性,可以分离更多的峰。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验